Reducing long acting antipsychotic injection dosage frequency: A pilot study in a community mental health team

References

• Barnes, T. R. E., Shingleton-Smith, A., & Paton, C. (2009). Antipsychotic long-acting injections: Prescribing practice in the UK. British Journal of Psychiatry, 195(S52), s37–s42. doi:10.1192/bjp.195.52.s37
   Google Scholar
• Bell, H., & Morris, R., W. (2017). An analysis of Mental Health NHS Benchmarking Network data for England and Wales. Retrieved from https://www.Centreformentalhealth.Org.Uk/Publications/Briefing-52-Adult-and-Older-Adult-Mental-Health-Services-2012-2016.
   Google Scholar
• Buckley, P. F., Schooler, N. R., Goff, D. C., Hsiao, J., Kopelowicz, A., Lauriello, J., … Kane, J. M. the PROACTIVE Study (2015). Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. Schizophrenia Bulletin, 41(2), 449–459. doi:10.1093/schbul/sbu067
   PubMed Web of Science ®Google Scholar
• Dalton, A., Lambert, T., Schrover, R., Hertel, J., & Smith, D. (2011). The cost associated with administering risperidone long-acting injections in the Australian community. BMC Health Services Research, 11(1), 236. doi:10.1186/1472-6963-11-236
   PubMedGoogle Scholar
• Herriot, P., & Kheirani, K. (2005). Survey of depot antipsychotic prescribing in southern Adelaide. Australasian Psychiatry, 13(3), 253–257. doi:10.1111/j.1440-1665.2005.02196.x
   PubMedGoogle Scholar
• Iyer, S., Banks, N., Roy, M.-A., Tibbo, P., Williams, R., Manchanda, R., … Malla, A. (2013). A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-service user perspectives. The Canadian Journal of Psychiatry, 58(5_suppl), 14–22S. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23945063. doi:10.1177/088740341305805s03
   Web of Science ®Google Scholar
• Jones, J. C., Day, J. C., Taylor, J. R., & Thomas, C. S. (1998). Investigation of depot neuroleptic injection site reactions. Psychiatric Bulletin, 22(10), 605–607. doi:10.1192/pb.22.10.605
   Google Scholar
• Kisely, S., Sawyer, E., Robinson, G., & Siskind, D. (2015). A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. Schizophrenia Research, 166(1-3), 178–186. doi:10.1016/j.schres.2015.04.028
   PubMed Web of Science ®Google Scholar
• Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., … Correll, C. U. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophrenia Bulletin, 40(1), 192–213. doi:10.1093/schbul/sbs150
   PubMed Web of Science ®Google Scholar
• Kumar, V., Rao, N. P., Narasimha, V., Sathyanarayanan, G., Muralidharan, K., Varambally, S., … Gangadhar, B. N. (2016). Antipsychotic dose in maintenance treatment of schizophrenia: A retrospective study. Psychiatry Research, 245, 311–316. doi:10.1016/j.psychres.2016.08.042
   PubMed Web of Science ®Google Scholar
• Lambert, T., Brennan, A., Castle, D., Kelly, D. L., & Conley, R. R. (2003). Perception of depot antipsychotics by mental health professionals. Journal of Psychiatric Practice, 9(3), 252–260. doi:10.1097/00131746-200305000-00011
   PubMedGoogle Scholar
• Marshall, M., & Lockwood, A. (2000). Assertive community treatment for people with severe mental disorders. The Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD001089
   Google Scholar
• Medicines Compendium (2019). Summary of product characteristics. Retrieved from: https://www.medicines.org.uk/emc.
   Google Scholar
• NHS/Health Research Authority (2018). Framework for Health and Social Care Research. Retrieved from: https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/.
   Google Scholar
• NICE (2014). Psychosis and schizophrenia in adults: Prevention and management. Clinical Guidelines, (178). doi:10.1002/14651858.CD010823.pub2.Copyright
   Google Scholar
• Nussbaum, A. M., & Stroup, T. S. (2012). Paliperidone palmitate for schizophrenia. Schizophrenia Bulletin, 38(6), 1124–1127. doi:10.1093/schbul/sbs099
   PubMed Web of Science ®Google Scholar
• Shi, L., Ascher-Svanum, H., Zhu, B., Faries, D., Montgomery, W., & Marder, S. R. (2007). Characteristics and use patterns of service users taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services, 58(4), 482–488. doi:10.1176/ps.2007.58.4.482
   PubMed Web of Science ®Google Scholar
• Uchida, H., Suzuki, T., Takeuchi, H., Arenovich, T., & Mamo, D. C. (2011). Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: Meta-analysis. Schizophrenia Bulletin, 37(4), 788–799. doi:10.1093/schbul/sbp149
   PubMed Web of Science ®Google Scholar
• Viggiano, T., Pincus, H. A., & Crystal, S. (2012). Care transition interventions in mental health. Current Opinion in Psychiatry, 25(6), 551–558. doi:10.1097/YCO.0b013e328358df75
   PubMed Web of Science ®Google Scholar
• Walburn, J., Gray, R., Gournay, K., Quraishi, S., & David, A. S. (2001). Systematic review of service user and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry, 179(4), 300–307. doi:10.1192/bjp.179.4.300
   PubMedGoogle Scholar
• Zhornitsk, S., & Stip, E. (2012). Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: A systematic review. Schizophr Res Treatment, 2012, 407171. doi:10.1155/2012/407171
   PubMedGoogle Scholar